WEST LAFAYETTE, Ind., April 8, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that Mike Sherman, chief financial officer of Endocyte, will present at the upcoming BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 15th, 2011, at 1:30 p.m. EDT at the Millennium Broadway Hotel in New York City.
A live audio webcast of the Company's presentation can be accessed at or under "Events & Presentations" in the Investor Relations section of Endocyte's website at . The webcast will be archived approximately one hour after the live event and a replay will be available on the Company's website.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
CONTACT: Stephanie Ascher Stern Investor Relations, Inc. (212) 362-1200 email@example.com Martina Schwarzkoph, Ph.D. Russo Partners, LLC (212) 845-4292 firstname.lastname@example.org